Leukemias, lymphomas, and other hematologic cancers:

Indications for: Cladribine

Active hairy cell leukemia.

Adult Dosage:

Give by continuous IV infusion for 7 consecutive days. 0.09mg/kg per day.

Children Dosage:

See full labeling.

Boxed Warning:

Administer under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Risk of neurological toxicity. Acute nephrotoxicity has been observed with high doses (esp. when concomitant with other nephrotoxic treatments).

Cladribine Warnings/Precautions:

Delay or discontinue if neurotoxicity or renal toxicity occurs. Myelosuppression. Active infection. Renal or hepatic insufficiency. Monitor blood counts (esp. during first 4–8 weeks post-dose), renal and hepatic function. Pregnancy (Cat.D), nursing mothers: not recommended.

Cladribine Classification:

Chlorinated purine nucleoside analog.

Cladribine Interactions:

Live attenuated vaccines: not recommended. Increased toxicity with myelosuppressive, immunosuppressive, or nephrotoxic agents.

Adverse Reactions:

Severe myelosuppression (eg, neutropenia, anemia, thrombocytopenia), fever, infection, fatigue, nausea, rash, headache, inj site reactions, others; neurotoxicity, nephrotoxicity, tumor lysis syndrome (rare).

Generic Drug Availability:


How Supplied:

Contact supplier.